Catching you up on the week of June 15–21, 2026: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
Reunion Neuroscience Inc.: Reunion Neuroscience appoints Sahil Kirpekar as President and CEO
Reunion Neuroscience named Sahil V. Kirpekar, M.D., as President and CEO and a board member, succeeding Greg Mayes. Kirpekar previously served as Chief Business Officer at atai Life Sciences (now AtaiBeckley), where he helped lead the acquisition of Beckley Psytech. He takes over as the privately held company advances luvesilocin (RE104), a short-duration psilocin-like prodrug that holds FDA Breakthrough Therapy Designation for postpartum depression, with Phase 2 trials underway in adjustment disorder and generalized anxiety disorder.
Source: globenewswire.com
Silo Pharma, Inc. (SILO): Silo Pharma regains compliance with Nasdaq minimum bid price requirement
Silo Pharma said Nasdaq confirmed that, as of June 17, 2026, it had regained compliance with the minimum closing bid price requirement under Listing Rule 5550(a)(2), removing a delisting risk. CEO Eric Weisblum said the company continues advancing its lead PTSD candidate SPC-15 toward a first-in-human trial. Regaining compliance stabilizes the micro-cap's listing status as it pursues its neuropsychiatric pipeline.
Source: investingnews.com
Clearmind Medicine Inc. (CMND): Clearmind Medicine granted U.S. patent for binge behavior regulators
Clearmind Medicine was granted U.S. Patent No. 12,350,242, titled 'Binge Behavior Regulators,' covering compositions and methods using its proprietary molecule MEAI (5-methoxy-2-aminoindane) to regulate binge behaviors such as excessive drinking, eating, and gambling. The grant strengthens the intellectual property protecting Clearmind's lead platform, which is being studied for alcohol use disorder. Expanded IP is a value driver for the small-cap developer as it advances its clinical program.
Source: manilatimes.net
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.